• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 95
  • 31
  • 27
  • 22
  • 21
  • 11
  • 8
  • 5
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1
  • Tagged with
  • 278
  • 100
  • 36
  • 31
  • 28
  • 24
  • 22
  • 21
  • 19
  • 19
  • 17
  • 17
  • 15
  • 14
  • 13
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
111

Glycine Transporter-1 Antagonist Provides Neuroprotection Following Stroke in Vivo

Cappelli, Julia Dominique 01 December 2021 (has links)
Ischemic strokes are a major cause of death and disability, yet efficacious pharmacotherapies remain limited. Although neuronal cell death during stroke is primarily induced via excessive Ca2+ influx through NMDARs following overactivation by uncontrolled glutamate release, antagonism of these receptors has been shown to be ineffective due to intolerable side effects. This thesis highlights a novel therapeutic strategy for stroke wherein NMDAR-mediated excitotoxicity is temporarily and dynamically mitigated via the initiation of a process termed “glycine induced NMDAR internalization” (GINI). While GINI occurs in vitro following application of high doses of glycine, achieving these levels of glycine in vivo has long been thought impossible as glycine transporters (GlyT1) maintain synaptic glycine levels well below saturating concentrations. Here, we show that GINI can be triggered in vivo when mice are administered a glycine transporter-1 antagonist (GlyT1-A) prior to stroke and that this strategy provides neuroprotection. Mice pre-treated with a GlyT1-A, which elevates glycine levels, exhibited significantly smaller stroke volumes, reduced cell death, and significantly minimized behavioural deficits following stroke induction by either photothrombosis (PT) or endothelin-1 (ET-1). Moreover, we observed preservation of vasculature function and morphology in the peri-infarct area. These data strongly suggest that elevating brain glycine levels with GlyT1-As should be considered as a novel pharmacotherapy for ischemic stroke.
112

Mechanisms of action of β-blockers for the treatment of heart failure

Burman, Jonas January 2020 (has links)
Heart failure is a syndrome in which the heart is unable to supply the entire body with oxygen. It is manifested in shortness of breath and exercise intolerance. One class of drugs that have proven effective in managing the progression of heart failure is β-blockers. These drugs bind to β-adrenergic receptors with high affinity, thus preventing the binding of endogenous catecholamines such as epinephrine and norepinephrine to the receptors by outcompeting them. The most common explanation of how β-blockers help manage the progression of heart failure is that by slowing the heart rate, it reduces the strain put on the heart. There may however be other ways that β-blockers help decrease morbidity and mortality of heart failure. Alternative reasons to how β-blockers aid the treatment of heart failure have been proposed based on the literature. It was found that the compensatory mechanisms intended to alleviate failure may be the main reasons that actually worsen it. Prolonged stimulation by epinephrine and norepinephrine damage the myocardium through oxidative damage, signaling for apoptosis and cardiac remodeling, as well as causing an increase in blood volume through the RAS-system. By blocking these maladaptive responses, β-blockers such as Carvedilol, Metoprolol and Nebivolol, together with other drugs such as ACE-inhibitors, and lifestyle changes help manage the progression of heart failure as well as increase the quality of life for the patients suffering from it
113

Der Einfluss von NMDA-Rezeptor-Modulatoren auf die Blut-Hirn Schranke unter ischämischen Bedingungen / The influence of NMDA receptor modulators on the blood-brain barrier under ischemic conditions

Gaiser, Fabian January 2020 (has links) (PDF)
Im Rahmen dieser Arbeit wurde das Motilitätsverhalten von Blut-Hirn Schranken-Endothelzellen unter ischämischen Bedingungen an Hand der cerebEND-Zelllinie untersucht. Da es bisher noch kein Modell für diese Fragestellung gab, wurde zunächst ein solches mit Hilfe des kommerziellen Motilitätsassay der Firma ibidi® etabliert. Danach konnte der Einfluss von ischämischen Bedingungen, von Astrozyten konditioniertem Medium (C6-Zelllinie) und letztendlich der therapeutische Ansatz durch Modulation des NMDA-Rezeptors untersucht werden. Dabei zeigte sich durch das C6-konditionierte Medium eine deutliche Zunahme der Motilität. Diese verstärkte Motilität konnte durch den NMDA-Rezeptor-Antagonisten MK801 verhindert werden. Trotz Analyse einiger an der Proliferation und Migration beteiligter Botenstoffe wie VEGF und MMPs konnte keine Regulation dieser durch MK801 nachgewiesen werden. / In this work, the motility behavior of blood-brain barrier endothelial cells under ischemic conditions was investigated using the cerebEND cell line. As there was no model for this question available until now, a model was first established using the commercial motility assay of the company ibidi®. Subsequently, the influence of ischemic conditions, astrocyte conditioned medium (C6-cell line) and finally the therapeutic approach by modulation of the NMDA receptor could be investigated. The C6-conditioned medium showed a significant increase in motility. This increased motility could be prevented by the NMDA receptor antagonist MK801. Despite analysis of some messenger substances involved in the proliferation and migration such as VEGF and MMPs, no regulation of these substances by MK801 could be detected.
114

Investigation of the neutrophil-directed anti-inflammatory properties of the cysteinyl leukotriene receptor antagonist, montelukast

Lodder, Cornelia Magdalena 26 April 2012 (has links)
Montelukast (ML) is primarily an antagonist of type 1 cysteinyl leukotriene receptors (CysLT1R), an activity which underpins its therapeutic efficacy in bronchial asthma. However, ML has also been reported to be useful in the treatment of acute and chronic inflammatory disorders of both infective and non-infective origin in which CysLTs are unlikely to be the predominant mediators of harmful inflammatory responses. These include conditions such as chronic obstructive pulmonary disease and cystic fibrosis in which the neutrophil is believed to be the primary offender, suggesting that ML may possess neutrophil-targeted, CysLT1R-independent mechanisms of anti-inflammatory activity. Accordingly, the laboratory research presented in this thesis was designed with the primary objectives of characterizing possible CysLT1R-dependent and – independent neutrophil-targeted anti-inflammatory activities of ML in vitro, and consisted of 3 phases. These were investigation of: i) the effects of the CysLTs, LTC4 and LTD4 (in the absence and presence of ML) on mobilization of intracellular Ca2+ stores, generation of reactive oxygen species (ROS) and release of primary and secondary granule proteinases; ii) the effects of ML on a series of pro-inflammatory activities of neutrophils following activation of the cells with the chemoattractants FMLP and platelet-activating factor (PAF); and iii) the interactive, anti-inflammatory effects on neutrophils of ML in combination with the long-acting beta-2 agonist, formoterol. In addition to the aforementioned activities, measurement of the production and expression of CR3, as well as generation of inositol triphosphate (IP3), cyclic AMP, and activities of the enzymes cAMP- and cGMP-phosphodiesterases (PDEs) in isolated neutrophil cytosol and membrane fractions, were also included. The following assays were used: i) chemiluminescence procedures for the detection of ROS; ii) a colourimetric procedure for the detection of elastase; iii) ELISA procedures for the detection of the matrix metalloproteinases (MMPs) 8- and -9, LTB4, and cyclic AMP; iv) fura-2-based spectrofluorimetry and a radiometric procedure for monitoring cytosolic Ca2+ fluxes; v) flow cytometry for CR3; and vi) radioassays for IP3 and activity of cAMP- and cGMP-PDEs. Exposure of neutrophils to LTD4, but not LTC4, activated a very modest and transient increase in cytosolic Ca2+, but failed to initiate the generation of ROS or release of elastase or MMP-8. However, brief pre-treatment with either LTC4 or LTD4 sensitized the cells for increased production of ROS and release of granule proteinases following activation with FMLP, which was partially attenuated by inclusion of ML. In the second part of the study, pre-treatment of neutrophils with ML, at therapeutically relevant concentrations, resulted in dose-related inhibition of the FMLP- or PAF-activated generation of ROS and LTB4, as well as the release of elastase, with the former being unaffected by an inhibitor of 5-lipoxygenase (MK886), compatible with a CysLT1R-independent mechanism of anti-inflammatory activity. From a mechanistic perspective, these interactions of ML with neutrophils were associated with accelerated clearance of Ca2+ from the cytosol of the cells which could not be attributed to inhibition of production of IP3, but was, however, associated with increased levels of cAMP, apparently as a consequence of non- specific inhibition of cyclic nucleotide phosphodiesterases. In the third part of the study, combining ML with formoterol caused (in most cases) additive inhibitory effects on the generation of ROS and LTB4, release of granule proteinases, as well as expression of CR3, which again were associated with elevations in cAMP and interference with Ca2+ mobilization. In conclusion, ML appears to attenuate neutrophil activation by CysLT1R-dependent and –independent mechanisms. In the case of the former by interfering with the modest sensitizing (priming) interactions of LTC4 and LTD4 with neutrophils, and in the latter by inhibition of PDEs, leading a to sustained elevation in cAMP, resulting in rapid clearance of Ca2+ from the cytosol and decreased uptake of the cation from the extracellular milieu. / Thesis (PhD)--University of Pretoria, 2011. / Immunology / Unrestricted
115

Ketamine for depression : The role of dissociative effects

Broström, Jakob January 2020 (has links)
Several trials have reported rapid antidepressant response from the anesthetic drug ketamine although the mechanism behind this effect is not fully understood. Research has focused mainly on ketamine’s action in the brain, including its effects on chemical balance, connections between brain cells and networks, and cognition. Trials with psychedelic drugs have had similar antidepressant results as ketamine, and the quality of the subjective psychedelic experience seems to mediate antidepressant action. Ketamine causes similar alterations of consciousness, which have been viewed as side effects. This thesis examines whether ketamine works in a similar way as psychedelics, where the ketamine-induced dissociative-like experience has a relationship to antidepressant response. Leading theories of depression and ketamine’s action in the brain are presented, and eight studies examining the relationship between ketamine-induced subjective experience and antidepressant response are reviewed. Three included studies found a relationship between psychedelic- and dissociative-like symptoms and reduction in depression, while five did not. The supposed relationship between psychedelic- and dissociative-like symptoms and antidepressant action has not been adequately explored and needs further examination in clinical trials.
116

Ketamine for treatment-resistant depression : Moving away from conventional antidepressants

Blom, Emma-Clara January 2021 (has links)
An increasing amount of research suggests Ketamine in subanaesthetic doses to be an effective antidepressant for Major Depressive Disorder (MDD) and Treatment-Resistant Disorder (TRD). After the finding that NMDA-receptor antagonists may hold antidepressant effect, several studies have suggested Ketamine to have great effect in relief of depressive symptoms. A time lag between biological and behavioural effects have been shown in currently available antidepressants and are not guaranteed to be efficient; only 30% of patients reach adequate response. The aim for this thesis is to systematically review available studies on the efficiency of Ketamine's antidepressant effects in patients with TRD. Scopus, Web of Science, and PubMed were the databases searched for relevant research regarding the subject. Six articles were included in the analysis. A compilation of the results presented a moderate to large effect size for Ketamine compared to placebo at 24 hours through day seven. It is of immense weight that prolonged adverse effects and possible abuse are taken into consideration for future research, as well as how to sustain the dramatic acute antidepressant effect of Ketamine.
117

Första anblicken av en karaktär i film : En undersökning om olika karaktärstypers introduktioner i filmerna Avatar (2009) och Lord of the Rings: The Fellowship of the Ring (Extended Edition, 2001)

Wiik, Rebecka, Sprenger, Fabian January 2022 (has links)
Uppsatsen undersöker hur de tre karaktärstyperna protagonist, antagonist och hjälte introduceras i de första bilderna i filmerna Avatar och Lord of the Rings: The Fellowship of the Ring utifrån berättarkomponenterna bildutsnitt, ljussättning, djupindikationer och ljud. Totalt sex karaktärsintroduktioner från filmerna kommer att analyseras och därefter jämföras med varandra. Det finns otroligt många olika metoder att introducera en karaktär på, som filmskapare är det viktigt att tänka på hur man vill att varje karaktär ska skildras. Därför kan den här uppsatsen ses som inspiration för hur en karaktär kan introduceras, då det inte finns ett definitivt svar.
118

Microvascular Permeability to Macromolecules and Its Dynamic Modulation.

Joyner, William L., Kern, David F. 01 January 1990 (has links)
This article presents current aspects of transvascular exchange for solutes and water in the microcirculation. Also discussed are various concepts concerning the modulation of the barrier in inflammatory-like states, as well as information describing the receptor-operated channels in endothelial cells and their processing.
119

Ontogenetic Serotoninergic Lesioning Alters Histaminergic Activity in Rats in Adulthood

Jośko, Jadwiga, Drab, Jacek, Jochem, Jerzy, Nowak, Przemyslaw, Szkilnik, Ryszard, Korossy-Mruk, Eva, Boron, Dariusz, Kostrzewa, Richard M., Brus, Halina, Brus, Ryszard 01 August 2011 (has links)
The aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats lesioned as neonates with the serotonin (5-HT) neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). At 3 days after birth Wistar rats were pretreated with desipramine (20 mg/kg ip) before bilateral icv administration of 5,7-DHT (37.5 μg base on each side) or saline-ascorbic (0.1%) vehicle (control). At 10 week levels of 5-HT and its metabolite 5-hydroxyindole acetic acid (5-HIAA) were determined in frontal cortex, striatum, and hippocampus by an HPLC/ED technique. In the hypothalamus, frontal cortex, hippocampus and medulla oblongata, the level of histamine was analyzed by an immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped activity) were performed, and effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists S(+)chlorpheniramine (H1), cimetidine (H2), and thioperamide (H3) were determined. We confirmed that 5,7-DHT profoundly reduced contents of 5-HT and 5-HIAA in the brain in adulthood. Histamine content was also reduced in all examined brain regions. Moreover, in 5,7-DHT-lesioned rats the locomotor and oral activity responses to thioperamide were altered, and apomorphineinduced stereotype was intensified. From the above, we conclude that an intact central serotoninergic system modulates histamine H3 receptor antagonist effects on the dopaminergic neurons in rats.
120

Treatment of Knee Osteoarthritis With Orthokine®-Derived Autologous Conditioned Serum

Fox, Beth A., Stephens, Mary M. 01 May 2010 (has links)
Osteoarthritis (OA) is the most prevalent arthritis in the world with increasing numbers of people expected to acquire the disease as the population ages. Therapies commonly used to manage the disease have limited efficacy and some carry significant risks. Current data suggest that the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1Ra) can alter the inflammatory response and cartilage erosion present in OA. Intra-articular gene expression of IL-1Ra has shown promising results in animal models to provide symptomatic improvement and minimize osteoarthritic changes. Orthogen AG (Dusseldorf, Germany) has developed a method to produce an autologous conditioned serum (ACS) rich in IL-1Ra marketed as Orthokine®. Study participants treated with ACS have improved pain and function; however, these results are preliminary and need confirmation. If ongoing trials prove that ACS can retard cartilage degeneration and reduce inflammation, the management of OA would be dramatically altered, perhaps providing a mechanism to prevent the disease or at least its progression.

Page generated in 0.0917 seconds